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Abstract
Background: Current quantitative methods for personalising psychotherapies for depression are unlikely to be able
to inform clinical decision-making for hundreds of years. Novel alternative methods to generate hypotheses for
prospective testing are therefore required, and we showcase mixed methods as one such approach. By exploring
patients’ perspectives in depth, and integrating qualitative and quantitative data at the level of the individual, we
may identify new potential psychosocial predictors of psychotherapy outcomes, potentially informing the
personalisation of depression treatment in a shorter timeframe. Using Morita therapy (a Japanese psychotherapy) as
an exemplar, we thus explored how Morita therapy recipients’ views on treatment acceptability explain their
adherence and response to treatment.
Methods: The Morita trial incorporated a pilot randomised controlled trial of Morita therapy versus treatment as
usual for depression, and post-treatment qualitative interviews. We recruited trial participants from general practice
record searches in Devon, UK, and purposively sampled data from 16 participants for our mixed methods analysis.
We developed typologies of participants’ views from our qualitative themes, and integrated these with quantitative
data on number of sessions attended and whether participants responded to treatment in a joint typologies and
statistics display. We enriched our analysis using participant vignettes to demonstrate each typology.
Results: We demonstrated that (1) participants who could identify with the principles of Morita therapy typically
responded to treatment, regardless of how many sessions they attended, whilst those whose orientation towards
treatment was incompatible with Morita therapy did not respond to treatment, again regardless of treatment
adherence and (2) participants whose personal circumstances impeded their opportunity to engage in Morita
therapy attended the fewest sessions, though still benefitted from treatment if the principles resonated with them.
Conclusions: We identified new potential relationships between “orientation” and outcomes, and “opportunity”
and adherence, which could not have been identified using existing non-integrative methods. This mixed methods
approach warrants replication in future trials and with other psychotherapies to generate hypotheses, based on
typologies (or profiles) of patients for whom a treatment is more or less likely to be suitable, to be tested in
prospective trials.
Trial registration: Current Controlled Trials, ISRCTN17544090. Registered on 23 July 2015.
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Background
Depression is the most common mental health disorder
and leading cause of disability worldwide [1–4]. Whilst
evidence indicates that antidepressant medication
(ADM) and several psychotherapies such as cognitive
behavioural therapy (CBT) are, on average, equally ef-
fective in treating depression [5, 6], there is also much
room for improvement: between one third and half of
patients do not respond to treatment, and many do not
adhere to treatment, thus impeding treatment effective-
ness [7–15]. Indeed, modelling studies show that treat-
ment can reduce the disease burden of depression in
only approximately 33% of patients [16].
As individuals vary widely in response to specific treat-
ments, one way to improve outcomes is to develop per-
sonalised depression treatments, or match patients to
treatments, by identifying which individual patient char-
acteristics predict treatment outcomes [17–19]. Persona-
lised medicine is considered both a priority and a
challenge for mental health researchers, and research on
predictors and moderators of outcome is of vital import-
ance [18–20].
Whilst research on differential response to ADM fo-
cuses on biomarkers, research on differential response to
psychotherapies has largely focused on quantitatively
measured clinical characteristics such as depression se-
verity, history and subtypes; comorbid conditions and
sociodemographic factors [17–19, 21]. However, such re-
search has produced only limited knowledge about who
benefits most from which treatment [17, 18], leaving
only a “trial and error approach” towards depression
treatment [22] (p.40). Efforts based on post hoc moder-
ator analysis have been largely unsuccessful [21], and a
recent review of randomised trials comparing two psy-
chotherapies in patients with 27 specific characteristics
indicates that completing sufficient trials to show an ef-
fect size of g = 0.50 would require another 326 years of
research [23]. Understanding how combinations of such
characteristics predict outcomes would require a longer
timeframe still [19].
Authors therefore advocate alternative methodological
approaches, especially those that can provide hypotheses
to be tested in future trials [19, 23]. Whilst some pro-
gress has been made in developing predictive models
combining various moderators to be tested in prospect-
ive trials (e.g. [24–26]), it can be argued therefore that
what is needed is not more patient numbers but more
understandings, to inform decision-making in a shorter
timeframe.
Mixed methods may be one alternative methodological
approach for generating such hypotheses. Rather than
categorising patients according to quantified clinical and
sociodemographic characteristics, using this approach
we can be guided by the views of individual patients
themselves: their attitudes, values and preferences in re-
lation to treatment acceptability. This understanding of
patients’ perspectives is key to personalising treatment;
it can be argued that if we seek to individualise treat-
ment, analysis should be at the level of the individual ra-
ther than the group [27] and augmenting quantitative
approaches with a deeper dive into the rich, narrative
data of individuals may enable us to best address indi-
vidual complexity [28].
As such, we may obtain understandings of potential
psychosocial predictors of treatment outcomes (or social
biomarkers [29]) to inform the personalisation of psy-
chotherapy for depression [30]. Whilst others argue for
the importance of such factors, the role of patients’
views on treatment acceptability as a potential moder-
ator of treatment outcomes has received little attention,
and any such studies typically rely on quantitative mea-
sures alone [31–35]. However, qualitative and mixed
methods have several potential advantages in this field.
Qualitative methods are well-suited to the study of these
social and experiential processes, which are imbued with
personal meanings and difficult to express in quantita-
tive terms [29, 36]. By taking an exploratory qualitative
approach, unconstrained by predefined variables, and in-
tegrating qualitative and quantitative data at the level of
the individual in a systematic and transparent manner
[37], we may identify unexpected yet empirically derived
variables based on patients’ perspectives, which poten-
tially explain treatment outcomes, to be evaluated in fu-
ture trials.
Using Morita therapy (MT) as an exemplar, we utilised
this novel mixed methods approach in the Morita trial.
The trial follows on from an iterative programme of
work conducted to develop our MT clinical protocol,
whereby we optimised MT according to the views of
stakeholders [38]. MT [39] is a Japanese psychotherapy,
informed by Zen Buddhist principles, with a holistic ap-
proach aiming to improve everyday functioning rather
than targeting specific symptoms [40, 41]. Key compo-
nents are outlined in Table 1. In the conceptual model
underpinning MT, unpleasant thoughts and emotions
are accepted as part of the natural ecology of the human
experience, which ebb and flow as a matter of course
and cannot be controlled by will. Accordingly, MT con-
trasts with the focus of established Western approaches,
such as CBT, on symptom control [42].
The Morita trial represented the first trial of MT in
the UK: a feasibility study encompassing a pilot rando-
mised controlled trial of MT plus treatment as usual
(TAU) versus TAU alone, and embedded qualitative inter-
views. We established that a large-scale MT trial is feasible
and that MT shows promise in treating depression. Our
qualitative results highlighted that (1) the extent to which
participants’ expectations and understandings of depression
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and its treatment (or their “orientation” towards treatment)
were compatible with MT, thus enabling or hindering their
identification with the principles of MT, was tied to the ex-
tent to which MT was perceived as acceptable and (2) there
is a distinction between engaging with MT on this concep-
tual level and engaging with MT on an operational level, with
some practical challenges identified. The protocol, quantita-
tive and qualitative results are reported elsewhere [43–45].
In our mixed methods study, reported here, we devel-
oped typologies of participants based on their qualitative
views regarding the acceptability of MT, and integrated
these with quantitative data to explore why individual
participants differed in terms of their adherence and re-
sponse to MT. Our aim was to understand whether pa-
tients’ perspectives can help to explain treatment
adherence and response, in order to continue our opti-
misation of MT, develop hypotheses to be tested in the
process evaluation of a future trial, and, ultimately, in-
form the personalisation of treatment.
Research questions
Our research questions are:
1. How do participants’ views about Morita therapy
relate to the variability in the number of treatment
sessions they attend?
2. How do participants’ views about Morita therapy
relate to whether they respond to treatment (≥ 50%
reduction in depressive symptoms (Patient Health
Questionnaire 9 (PHQ-9) [46]) from baseline to
follow up)?
Methods
Design and aim
We employed a mixed methods embedded design [47]
guided by a pragmatic philosophy [37]. For the quantita-
tive and qualitative components (reported elsewhere)
[44, 45], we collected data concurrently and analysed
data sequentially (with quantitative data informing our
sampling of qualitative interviews for analysis). We gave
these components equal priority and mixed them inter-
actively at the design and analysis levels. Our aim was to
explore how qualitative data on acceptability explains
treatment adherence and response.
Setting, recruitment and data collection
Our full quantitative and qualitative methods are re-
ported separately [44, 45]; a summary is presented here
to provide context for our mixed methods analysis. In
the Morita trial, we recruited 68 participants with major
depressive disorder, with or without anxiety disorder(s),
through general practice record searches in Devon, UK
Table 1 Key components of Morita therapy (MT)
Components Definition
Principles Natural world MT conceptualises unpleasant thoughts and emotions as part of natural human experience. It draws
upon the natural world, and the place of humans within it, to emphasise that symptoms are not
subject to the patient’s control, and will naturally ebb and flow with time
Acceptance and allowance of
internal states
All emotions and thoughts (internal states) are accepted as they are. Any attempts to control, resist,
avoid or intervene in symptoms are considered to exacerbate them within a vicious cycle; therapists
thus help patients to move away from symptom preoccupation and combat and towards acceptance
and action-taking. Thus, the objectives are to shift attention and perspective, and move patients to a
position of accepting and responding to phenomenological reality as it is, rather than controlling or
“fixing” symptoms
Normalisation Therapists label internal states as “unpleasant” and “pleasant” but not “good” or “bad”. They emphasise
that all emotions are natural, or normal, and will ebb and flow on their own so long as attempts are
not made to resist them
Fumon (inattention to
symptoms)
Therapists, in an effort to shift patients’ attention away from symptom preoccupation and combat, will
not focus on discussion or analysis of patients’ symptoms or their causes, but will “steer” the
conversation towards action-taking and the external environment
Process/
practice
Diaries Patients complete daily diaries on which therapists provide comments to facilitate an acceptance of
internal states and refocus attention on action-taking and the external environment
Four-phased model Rest and action-taking are structured within 4 phases: (1) rest; (2) light repetitive activities; (3) more chal-
lenging activities; (4) social reintegration. The process is understood to aid experiential acceptance of
the natural ebb and flow of internal states; re-orientate patients in nature; and refocus attention from
the “self”/internal states to external reality
Rest MT seeks to potentiate patients’ natural healing capacities, in contrast to resisting and exacerbating
symptoms. Patients sit with their internal states as they are, to learn how they naturally ebb and flow
with time if left unattended, and to build a natural desire to take action
Action-taking with symptoms Patients learn to undertake purposeful and necessary action, with or without their symptoms; action
which is driven by “desire for life” rather than a desire to change internal states. MT thus aims to
improve everyday functioning in spite of symptoms, with symptoms reducing as a by-product of mov-
ing from a mood-oriented to purpose-oriented and action-based lifestyle
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and randomised them to receive TAU or TAU plus 8–
12 sessions of MT delivered by trained therapists at the
University of Exeter’s AccEPT clinic following our MT
clinical protocol [38]. With the participant’s consent, we
audio-recorded all therapy sessions.
We collected the following data at baseline and 4
months post-baseline: severity of depressive symptoms
(PHQ-9) and generalised anxiety symptoms (Generalised
Anxiety Disorder questionnaire 7 [48]); quality of life
(Short Form 36 Health Survey Questionnaire [49] and
Work and Social Adjustment Scale [50]) and attitudes
(Morita Attitudinal Scale for Arugamama [51]). For MT
participants, we recorded the number of therapy sessions
attended and reason for ending treatment. We com-
pleted post-treatment semi-structured interviews with
consenting MT participants (n = 28) to explore their
views of MT using a topic guide based on recent mental
health trials addressing similar questions [13, 52, 53],
MT literature and our MT optimisation study findings
[38]. With participants’ permission, interviews were
audio-recorded and transcribed verbatim. We managed
qualitative data in NVivo10 [54] and analysed data using
framework analysis [55].
Sampling
Using a nested sampling design, we analysed mixed
methods data from a sub-sample of participants [56, 57].
Thus, we purposively selected “key informants” ([56]
p.240) on acceptability according to the following theor-
etically driven criteria deemed important in answering
our research questions [57, 58]: (1) treatment adherence
and (2) treatment response. To achieve maximum vari-
ation according to these criteria [58], we intended to in-
clude a quota of three participants within each subgroup
in the resulting sampling matrix (Table 2) [57]. Where a
larger number of participants comprised a subgroup (i.e.
those who completed and responded to treatment), we
further purposively sampled participants to ensure rep-
resentation across the following criteria: presence or not
of generalised anxiety disorder at baseline; participants’
experience or not of CBT; participants’ gender and ther-
apist. Through utilising a combination of probability and
purposive sampling orientations within a strategy suited
to mixed methods research, we thus aimed to both cap-
ture the breadth of views on acceptability and explore
the depth and diversity of views within each subgroup
[55, 59].
Analysis
Following separate analyses of the quantitative and
qualitative data (reported elsewhere) [44, 45], we devel-
oped typologies of participants’ views of MT from our
qualitative themes. We developed these typologies along
two continuums representing the acceptability of (1) the
MT principles and (2) the MT process, reflecting the
distinction between engaging with MT on conceptual
and operational levels, which ran through our qualitative
findings. For each typology, we developed example par-
ticipant vignettes from the qualitative data to illustrate
the key features that define that typology. We then inte-
grated data in a joint typologies and statistics display
[47]. In this display, organised by typology, we included
quantitative data on the number of treatment sessions
attended by each participant, the mean number of ses-
sions attended by all participants within each typology,
participants’ reasons for withdrawing from treatment
and whether or not they demonstrated a response to
treatment.
To guard against the possibility of alternative explana-
tions for our findings, where the qualitative data sug-
gested confusion related to particular components of
therapy (such as participants’ understanding of the pur-
pose of “rest”) we confirmed that therapists showed fi-
delity to the therapy protocol by reviewing audio-
recordings of relevant therapy sessions.
We describe our study in line with mixed methods
reporting guidelines (see Additional file 1 for completed
GRAMMS checklist) [60].
Results
We included data from 16 participants in our analysis
(Table 2): all participants who did not complete and/or
did not respond to treatment (n = 10) and 6 who com-
pleted and responded to treatment. Participant charac-
teristics are provided in Table 3.
We developed five typologies (Fig. 1). In Fig. 1, the
horizontal axis (from unacceptable principles to accept-
able principles) represents the extent to which the MT
principles (Table 1) were considered acceptable; the ver-
tical axis (from unacceptable practice/process to accept-
able practice/process) represents the extent to which the
Table 2 Sample
Adherence to treatment
Withdrew < 5
sessions
Withdrew ≥ 5
sessions
Completed
treatment
Treatment response?
(≥ 50% reduction in depressive symptoms (Patient Health Questionnaire-9) from
baseline to follow-up)
Yes n = 3 n = 1 n = 6
No n = 2 n = 3 n = 1
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Table 3 Participant characteristics
Characteristic Number (percemtage) unless otherwise stated
Total n = 16
Gender
Female 9 (56)
Age (years)
Mean (SD) 48 (12)
Ethnic origin
White British 16 (100)
Education
No qualifications 1 (6)
GCSE or O Level 3 (19)
Post GCSE or O Level 4 (25)
Undergraduate degree 4 (25)
Postgraduate qualification or higher 4 (25)
Marital status
Married or cohabiting 10 (63)
Number of children
Mean (SD) 1 (1)
PHQ-9 (depression) score
Mean (SD) at baseline 17 (5)
Mean (SD) at follow up 9 (7)
50% reduction in PHQ-9 score from baseline to follow up 10 (63)
Adherence to Morita therapy
Number of sessions attended (mean (SD)) 7 (4)
Completed treatment 7 (44)
Withdrew ≥ 5 sessions 4 (25)
Withdrew < 5 sessions 5 (31)
Morita therapist (of two available)
Therapist 01 8 (50)
Secondary SCID diagnoses (at baseline)
Any anxiety disorder 10 (63)
Generalised anxiety disorder 7 (44)
Panic disorder with agoraphobia 4 (25)
Panic disorder without agoraphobia 4 (25)
Social phobia 2 (13)
Post-traumatic stress disorder 1 (6)
Obsessive compulsive disorder 1 (6)
Previous psychotherapy/counselling (at least one course)
Any psychotherapy (not including counselling) 12 (75)
Cognitive behavioural therapy 10 (63)
Mindfulness-based cognitive therapy 4 (25)
Eye movement desensitization and reprocessing 1 (6)
Other psychotherapy 4 (25)
Counselling 8 (50)
Percentages may not always total 100, due to rounding
PHQ-9 Patient Health Questionnaire 9, SCID Structured Clinical Interview for DSM-IV disorders, SD standard deviation
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process and practice of MT (Table 1) were considered ac-
ceptable. The size of each typology represents the number
of participants whose views fall within that typology. Fol-
lowing our joint display (Table 4), each typology is de-
scribed in detail, in relation to the quantitative data and
alongside example participant vignettes. Participants are
referred to by trial ID number (MT__).
Typology 1: principles unacceptable; process/practice
unacceptable
The typology that appears at the bottom left of Fig. 1
represents the views of participants (MT19; MT28;
MT51; MT61) who considered both the principles and
practice of MT unacceptable. These participants all
expressed an orientation towards treatment (expecta-
tions or understandings of depression and its treatment)
that was incompatible with MT, such as seeking a cure
for symptoms or in-depth self-analysis. They also
expressed challenges of engaging with MT, which they
considered insurmountable, such as the pressure of
completing activities associated with the treatment
phases. Rarely were such challenges expressed as insur-
mountable because of participants’ demanding personal
circumstances, such as a lack of time; rather, these par-
ticipants focused on the challenges of treatment regard-
less of their circumstances and often in the context of
the treatment components failing to achieve the purpose
assigned to them in relation to the participant’s particu-
lar orientation towards treatment (such as helping them
to control symptoms).
Example vignette. MT61 approached treatment seek-
ing an opportunity to “open-up”, and answers to enable
them to stop unpleasant thoughts and feelings. MT61
struggled to identify with the MT principles: neither the
ebb and flow of emotions nor understanding emotions
through reference to nature resonated for them. MT61
misunderstood the purpose of rest as an opportunity for
the therapist to analyse their sleep, potentially to under-
stand more about them on an unconscious level, and con-
sidered it unrealistic to schedule and report on their sleep
in this way. MT61 discontinued treatment after three ses-
sions due to the discomfort of writing about themselves in
the diary, in the context of disliking themselves.
These participants who found both the principles and
practice unacceptable attended, on average, 5 treatment
sessions (range 3–7) of a maximum of 12 before discon-
tinuing treatment (for treatment-related reasons)
(Table 4). None responded to treatment.
Typology 5: principles acceptable; process/practice
acceptable
In contrast to typology 1, the typology that appears at
the top right of Fig. 1 represents the views of partici-
pants (MT16; MT33; MT43; MT45; MT55; MT63) who
considered both the principles and practice of MT ac-
ceptable. These participants all identified with and were
receptive to the MT principles, finding they resonated
with their experiences and views of depression. In
addition, whilst typically expressing some challenges of
engaging in treatment such as the discomfort of “sitting
with” unpleasant emotions during rest, these participants
considered them tolerable and worthwhile. These views
appeared to be facilitated by accurate understandings of
the purpose of these treatment components as part of a
progressive process for learning and re-focusing attention.
Fig. 1 Typologies of acceptability
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Example vignette. MT63 identified strongly with the
underlying premise of understanding unpleasant
thoughts and emotions as part of the natural human ex-
perience. Whilst noting that sitting with their thoughts
was “terrifying”, MT63 understood the purpose of rest
and learned the futility of engaging in the vicious cycle,
as per their normal coping strategies, therefore consider-
ing these challenges worthwhile. MT63 also described
the diary and spending time in nature in terms of learn-
ing how all things naturally pass. MT63 appreciated MT
as a gentle, natural process of self-discovery, noting the
value of an experiential approach, which had visceral,
emotional and intellectual impact. MT63 experienced
benefits of treatment in terms of normalising difficulties;
increasing action-taking; decreasing self-criticism and
symptoms. Compared with other treatments, MT63 felt
that MT had fundamentally changed their attitude
towards and acceptance of difficulties, as opposed to
providing strategies for tackling symptoms which poten-
tially “feed into” the vicious cycle.
These participants who found both the principles and
practice acceptable attended, on average, 10.8 treatment
sessions (range 9–12) (Table 4). All completed and
responded to treatment.
Typology 4: principles acceptable; mixed views on
process/practice
The typology that appears on the right of the x axis and
middle of the y axis of Fig. 1 represents the views of par-
ticipants (MT15; MT17; MT37; MT50) who, whilst simi-
larly identifying with the MT principles as per typology
5, experienced more significant challenges with the MT
process. Typically, these challenges related to the time
commitment and the discomfort associated with rest.
Table 4 Joint typologies (acceptability) and statistics (adherence) display
Typology of acceptability Trial
ID
Therapy sessions,
number
Reason for withdrawing from treatment
(N/A = completed treatment)
Treatment response?a
Each Mean
(1) Principles: unacceptable (incompatibility
with expectations/ hopes for treatment);
process/practice: unacceptable
(treatment-related challenges)
MT61 3 5 Discomfort with writing about self in diary;
failure of rest to meet expected purpose
No
MT19 5 Pressure of completing phases in absence
of therapy fulfilling expected purpose
No
MT51 5 Lack of techniques provided; challenges of rest
in context of not fulfilling expected purpose
No
MT28 7 Pressure of completing phases in absence
of therapy fulfilling expected purpose
No
(2) Principles: mixed views (limited
identification with principles);
process/practice: mixed views (treatment
related and non-treatment related
challenges; insurmountable)
MT54 1 N/A Time difficulties (rest/diary); difficulties with
Fumon (therapists’ inattention to symptoms)
Yes (attributed to life changes)
(3) Principles: mixed views
(limited identification with principles);
process/practice: acceptable (some
challenges; tolerated/worthwhile)
MT58 9 N/A N/A No
(4) Principles: acceptable (strong
identification with principles);
process/practice: mixed views (treatment
related and non-treatment related
challenges; insurmountable)
MT17 2 3.5 Time difficulties (rest) No
MT50 2 Safety issues (personal relationships) during rest Yes
MT15 3 Time difficulties (rest); no longer felt need
for therapy
Yes
MT37 7 Time difficulties (attending sessions);
no longer felt need for therapy
Yes
(5) Principles: acceptable (strong
identification with principles);
process/practice: acceptable (some
challenges; tolerated/ worthwhile)
MT33 9 10.8 N/A Yes
MT63 10 N/A Yes
MT45 11 N/A Yes
MT55 11 N/A Yes
MT16 12 N/A Yes
MT43 12 N/A Yes
N/A not applicable
aTreatment response defined as ≥ 50% reduction in depressive symptoms (Patient Health Questionnaire-9 (PHQ-9)) from baseline to follow up
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These participants considered these challenges insur-
mountable in the context of their personal circum-
stances, such as other commitments or a lack of safety
and social support during rest. Thus, unlike typology 1,
these participants were keen to continue MT (which
connected to their identification with the principles) and
accurately understood the treatment components as part
of a process, but found it unfeasible to engage with MT
at this point in their lives.
Example vignette. MT50 found that the principles
strongly resonated with them: understanding human
emotion as cyclic and through reference to nature, both
learning to be with unpleasant internal states and learn-
ing to take small steps of action, and nurturing one’s au-
thentic self. Accordingly, MT50 hoped that treatment
would help them to be more at ease with their feelings
and to take more action in line with their values. MT50
expressed an accurate understanding of the purpose of
therapy as a process for learning. MT50 engaged in one
day of rest and, whilst describing some discomfort,
noted a valuable lesson learned in terms of realising un-
pleasant internal states come and go. MT50 wanted to
continue therapy but withdrew after two sessions as they
felt unsafe resting at home in the context of a threaten-
ing neighbour. MT50 expressed significant benefits of
treatment in terms of knowing symptoms will pass (like
the weather), thus having more acceptance and less fear
of them, consequently finding they pass more quickly.
MT50 considered MT a “philosophy for life” and other
treatments as short-term fixes that risk highlighting and
exacerbating symptoms.
These participants who found the principles acceptable
and practice unacceptable withdrew because of the prac-
tical challenges of engaging with MT in the context of
their personal circumstances, alongside at times feeling
that they no longer required therapy (Table 4). They
attended, on average, 3.5 treatment sessions (range 2–7)
and all but one (MT17) responded to treatment, al-
though MT17 did show an improvement in symptoms.
Typologies 2 and 3: mixed views on principles
Within the sample of interviews analysed, the typologies
in the middle of the x axis of Fig. 1 were more anomal-
ous, representing two participants (MT58; MT54) who
expressed some identification with and/or positive views
of the principles alongside some expectations and hopes
for treatment that were incompatible with MT.
Firstly, MT54 (typology 2: mixed views on process/
practice) expressed interest in the ideas of MT and in
therapy involving a process. However, MT54 had been
receiving private counselling which, if affordable, they
would have continued. As such, MT54 struggled with
Fumon (therapists’ inattention to symptoms), feeling
that this “shut them down” and inhibited their rapport
with the therapist. MT54 also expressed significant chal-
lenges associated with the time commitment of rest and
diary completion in the context of childcare commit-
ments. MT54 discontinued treatment for these reasons
after attending one session (Table 4). MT54 responded
to treatment but attributed this to changed life circum-
stances rather than treatment.
Secondly, MT58 (typology 3: process/practice accept-
able) expressed identification with certain principles
such as the vicious cycle. However, MT58 also sought to
overcome their difficulties and tended to isolate each
treatment component as a potential tool for tackling or
distracting from symptoms. MT58 expressed challenges
of engaging with MT related to these inaccurate under-
standings of the purpose, such as struggling to “shut
out” thoughts during rest. However, MT58 considered
the challenges tolerable and did not refer to difficulties
in the context of demanding personal circumstances.
MT58 indicated some benefits of treatment, such as re-
duced engagement in the vicious cycle, but intended to
seek counselling and hoped that they would overcome
their difficulties in time. MT58 completed treatment at
nine sessions but did not respond to treatment
(Table 4).
Discussion
We found that our novel mixed methods approach can
identify potential predictors of treatment outcomes,
based on an individual’s attitudes and circumstances,
which could not be derived from existing non-
integrative methods for personalising depression treat-
ment. In our example, participants who could identify
with the MT principles typically responded to treatment
regardless of the number of sessions they attended; con-
versely, those whose orientation towards treatment was
incompatible with MT did not respond to treatment,
again regardless of treatment adherence. Participants
whose personal circumstances impeded their opportun-
ity to engage in treatment generally attended the fewest
number of sessions.
Thus, participants who considered both the MT prin-
ciples and process unacceptable (associated with holding
expectations or understandings of depression and its
treatment that are incompatible with MT) discontinued
treatment at between one and seven sessions; none
responded to treatment. Participants who considered
both the MT principles and process acceptable (express-
ing a strong identification with the principles alongside
some worthwhile practical challenges) attended the most
sessions; all responded to treatment. Participants with
mixed views on acceptability (expressing a strong identi-
fication with the principles yet significant challenges of
engaging with the process given their personal circum-
stances) discontinued treatment having attended the
Sugg et al. Trials           (2020) 21:41 Page 8 of 12
fewest sessions; however, they typically responded to
treatment.
Strengths and limitations
A key strength of this study is that it we have integrated
our quantitative and qualitative data at the level of the
individual and at the point of analysis, as opposed to at
the point of discussion (as per typical mixed methods
studies) [37]. Our identification of potential relationships
between acceptability, adherence and response would
not have been possible from a separate examination of
the group-based quantitative and qualitative results
alone, and is unlikely to have been possible from a com-
parison of such results within only the discussion. Fur-
thermore, by integrating individual-level quantitative
and qualitative data at the point of analysis in a system-
atic, transparent and rigorous manner, we produce con-
clusions that can be readily traced, understood and
interrogated [37]. We further enriched our analysis and
the meaningfulness of our findings by including partici-
pant vignettes and a confirmation of therapist fidelity
where relevant, and we describe our study in line with
mixed methods reporting guidelines [60].
In light of the current dearth of explicit examples of
both the use and usefulness of integrative mixed
methods analysis [61, 62], we therefore provide an ex-
ample of how research questions can be designed to spe-
cifically address the integration of data, how such
integration can be undertaken with rigour, and how such
integration can generate additional learning, thus adding
value through producing “a whole … that is greater than
the sum of the individual qualitative and quantitative
parts” [61] (p.116).
A potential limitation of this study relates to the
number and range of cases included. Whilst little
guidance is currently available on the appropriate
sample size for mixed methods analysis, it is likely
that considerations of the study purpose and hetero-
geneity of data are relevant. In this study, the overall
sample size, and the sample size of each subgroup
(e.g. those who completed but did not respond to
treatment), was constrained by the number of partici-
pants in the Morita trial who fulfilled our sampling
criteria. However, we purposively and explicitly se-
lected participants in order to achieve maximum vari-
ation along the target dimensions of our mixed
methods analysis (i.e. treatment adherence and re-
sponse), with only additional participants who com-
pleted and responded to treatment not sampled.
Nonetheless, our results are based on a limited
amount of data and may not reflect the relationship
between acceptability and outcomes in full, or be
transferable to other contexts such as different
psychotherapies.
Clinical implications
Whilst our findings regarding orientation and opportun-
ity as potential predictors of outcomes in MT will in-
form our process evaluation within any large-scale trial
of MT [63], they also provide us with tentative insights
that warrant further investigation in relation to other
psychotherapies for depression. Consistent with our
findings regarding participants’ orientation towards
treatment, other studies (whilst not including mixed
methods analysis) have suggested the importance of
matching patient perceptions and expectations to the
conceptual model underlying psychotherapy (including
CBT, psychodynamic therapy and behavioural activa-
tion) [31, 64]. Whilst our findings suggest that patients
who identify with allowing (as opposed to controlling)
internal states may be more likely to respond to MT,
others suggest the opposite pattern may be present in
cognitive therapy [65], which would be consistent with
the contrasting principles of these approaches. Thus,
whether the degree of concordance between a patient’s
orientation and the conceptual model of the treatment
approach may predict treatment response, and poten-
tially guide the matching of individuals to different psy-
chotherapies, warrants further investigation.
Furthermore, noteworthy within our current findings
is that this concordance appeared to override treatment
adherence in explaining treatment outcomes: partici-
pants who identified with the principles of MT typically
responded to treatment regardless of the number of ses-
sions they attended (and vice versa). Though highly
speculative, this suggests the potential importance of pa-
tients engaging with (the premise of) psychotherapy over
and above adhering to psychotherapy by rote. Distin-
guishing between engagement and adherence in psycho-
therapy in terms of their relationship to outcomes is an
area for further research.
If replicated, our findings might also inform the tailor-
ing of specific psychotherapies, in terms of the optimal
treatment “dose” for different patients. In MT, we might
tailor the approach to the needs of patients who identify
with the principles but experience demanding personal
circumstances (thus impeding their opportunity to con-
tinue MT) by developing a form of “low-intensity” MT,
comparable to low-intensity CBT [66], with reduced en-
gagement in the four treatment phases. Thus, we may
ultimately develop a clinical algorithm whereby patients
are matched to MT on the basis of their compatible
orientation towards treatment, and stratified to low-
intensity or high-intensity MT on the basis of their per-
sonal circumstances. More widely, whilst the current
movement towards reducing therapy intensity is driven
primarily by cost-savings to improve overall access to
therapy [67], our findings point to the potential for a
more coherent rationale based on the views and needs
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of patients themselves. Thus, the provision of low-
intensity options for suitable patients may constitute
“minimally disruptive medicine”: a necessary and benefi-
cial reduction in the burden of treatment based on the
realities of (certain) patients’ lives [68] (p.1).
Methodological implications
The development of personalised treatments is a major
priority for mental health researchers, yet current
methods are unlikely to be able to inform clinical
decision-making for hundreds of years [20, 23]. We have
showcased mixed methods research as an alternative
and novel methodological approach, which includes a
deep exploration of patients’ perspectives and the inte-
gration of qualitative and quantitative data at the level of
the individual. By focusing on these individual-level data
and not being constrained by predefined variables, this
exploratory method can enable us to identify new and
unexpected potential predictors of treatment outcomes
to be tested in prospective trials; predictors that are
empirically-driven (unlike many of those currently ex-
amined in trials [23]) and that could not be identified
using existing non-integrative methods. Our mixed
methods approach can therefore meet a current need in
the personalisation of treatment: the development of hy-
potheses for future testing, in order to personalise de-
pression treatment in a shorter timeframe [23].
Furthermore, through focusing on patients’ views,
values and circumstances in relation to treatment ac-
ceptability, mixed methods can identify potential psycho-
social predictors of treatment outcomes, combined in a
meaningful way in the form of typologies (or profiles) of
patients for whom a treatment may be more or less suit-
able. Such psychosocial factors have received relatively
little attention in personalising treatment, despite poten-
tially playing an important role in improving our cur-
rently limited understanding of not only whether a
patient with a certain characteristic will or will not ad-
here/respond to treatment, but why [29, 34, 69]. We
therefore recommend that mixed methods analysis be in-
corporated into trials of other psychotherapies for depres-
sion, in order to generate hypotheses for testing in
prospective trials, and ultimately inform both the match-
ing of different treatments to patients and the tailoring of
specific treatments to patients on the basis of the attitudes
and circumstances of individual patients themselves.
Conclusions
Our novel mixed methods approach can inform perso-
nalised trials and treatments by identifying potential pre-
dictors of treatment outcomes that would be missed by
existing non-integrative approaches. With current quan-
titative methods unlikely to be able to inform clinical
decision-making for hundreds of years, we argue for this
consideration of depth rather than breadth in the per-
sonalisation of treatment: integrating rich qualitative
data (requiring smaller patient numbers) with quantita-
tive data at the level of the individual in order to identify
unexpected potential psychosocial predictors of treat-
ment outcomes is an alternative worth pursuing. We
therefore recommend the replication of these methods
with other psychotherapies for depression, to investigate
whether key potential predictors in Morita therapy (par-
ticipants’ orientation and opportunity) may apply across
treatments, and with a view to continued hypothesis
generation for testing in prospective trials. Thus, this
methodological approach may inform the development
of both better trials and better treatments, and, ultim-
ately, the personalisation of psychotherapies based on
the attitudes and circumstances of individual patients.
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